Skip to search formSkip to main contentSkip to account menu

opicapone

Known as: 2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine 1-oxide 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Catechol-O-methyltransferase inhibitorOxadiazoles

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Pharmacokinetic Comparison of Capsule and Tablet Formulations of Opicapone in Healthy Japanese Subjects: Phase 1 Study
Opicapone, a peripheral, long‐acting catechol‐O‐methyltransferase inhibitor has been shown to improve wearing‐off phenomenon in… 
2019
2019
127EFFICACY AND SAFETY OF OPICAPONE IN PATIENTS OVER 70 YEARS WITH PARKINSON’S DISEASE AND MOTOR FLUCTUATIONS
2017
2017
Opicapone in Parkinson’s disease: a profile of its use
Oral opicapone (Ongentys®), a potent, third-generation, long-acting, peripheral catechol-O-methyltransferase (COMT) inhibitor, is… 
2016
2016
Development of a liquid chromatography assay for the determination of opicapone and BIA 9-1079 in rat matrices.
Opicapone is a novel potent, reversible and purely peripheral third generation catechol-O-methyltransferase inhibitor, currently… 
2015
2015
Opicapone significantly improves OFF-time in fluctuating Parkinson’s Disease patients as add-on to levodopa
  • 2015
  • Corpus ID: 15051765
PORTO, PORTUGAL, Thursday 19 March 2015 – BIAL announced results from a Phase III, randomized, double-blind, activeand placebo… 
2015
2015
Metabolism of Opicapone, a Novel COMT Inhibitor: Characterization of In Vitro Glucuronidation
Opicapone, is a novel catechol‐O‐methyltransferase inhibitor, currently in phase III of clinical trials. In this study the… 
2014
2014
Pharmacological Profile of Opicapone in Wistar rat
2013
2013
An HPLC-DAD method for the simultaneous quantification of opicapone (BIA 9-1067) and its active metabolite in human plasma.
Opicapone (BIA 9-1067) is a novel catechol-O-methyltransferase inhibitor presently under clinical development as an adjuvant in… 
2013
2013
Efficacy and safety of opicapone, a new COMT-inhibitor, for the treatment of motor fluctuations in Parkinson's Disease patients: BIPARK-II study
2012
2012
The design of a double-blind, placebo-controlled, multi-national phase-III trial in patients with Parkinson's disease and end-of-dose motor fluctuations: Opicapone superiority vs. placebo
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)